CJC-1295
Also known as: CJC-1295 DAC, CJC-1295 no DAC, Modified GRF 1-29
Key Facts: CJC-1295
- Category
- Growth Hormone
- FDA Status
- Not FDA Approved
- Clinical Status
- Investigational - Clinical trials conducted
- Administration
- Subcutaneous injection
- Typical Dose
- 100 mcg daily (no DAC) or 2 mg weekly (with DAC)
- Frequency
- Daily (no DAC) or 1-2x weekly (with DAC)
- Evidence Level
- Human Trials
- Duration
- 8-12 weeks
What to Expect
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Mechanism of Action
CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes.
Research Summary
Studies show sustained elevation of GH and IGF-1 levels. Research demonstrates 2-10 fold increase in GH levels depending on dose and formulation. Combination with GHRP produces synergistic GH release greater than either alone.
Dosing Information
Typical Dosingⓘ
Community experience
100 mcg daily (no DAC) or 2 mg weekly (with DAC)
100-300 mcg per dose (no DAC), 1-2 mg weekly (DAC)
Daily (no DAC) or 1-2x weekly (with DAC)
No-DAC version requires daily dosing. DAC version has longer half-life. Often stacked with GHRP like Ipamorelin.
Research Dosingⓘ
Scientific studies
Doses observed in research studies
Doses from Studies
CJC-1295 DAC: 1-2mg weekly
Mod GRF 1-29: 100-300 mcg 2-3x daily
Duration
8-12 weeks
Administration
Subcutaneous injection
Timing & Administration
Best Time to Take
Before bed
1-2 times per week
Food Recommendation
Take on empty stomach
Why This Timing?
CJC-1295 (with DAC) has a long half-life (~8 days) so timing is less critical, but evening dosing supports natural GH patterns.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Injection site reactions
- ●Facial flushing
- ●Headache
- ●Water retention
- ●Dizziness
- ●May trigger histamine release - use caution with MCAS or histamine sensitivity
- ●Concerns for cancer patients (IGF-1/GH effects)
- ●Risk of immunogenicity
References
Related Peptides
Peptides commonly compared with CJC-1295 or used in similar applications.
Ipamorelin
Clinical TrialsA selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Growth HormoneGHRP-6
Clinical TrialsOne of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.
Growth HormoneGHRP-2
Clinical TrialsA synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.
Growth HormoneMK-677
Clinical TrialsAn orally active growth hormone secretagogue that mimics ghrelin. Not a peptide technically, but frequently discussed alongside GH peptides due to similar effects.
Growth HormoneTesamorelin
FDAAn FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. One of the few peptides with FDA approval.
Growth HormoneSermorelin
PreclinicalA truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.
Growth HormoneWant updates on CJC-1295 research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.